Clinical Investigation of Plasma Copeptin Level on Major Adverse Cardiovascular Event in Patients With Acute ST-segment Elevation Myocardial Infarction During Hospitalization / 中国循环杂志
Chinese Circulation Journal
; (12): 13-16, 2015.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-462676
Biblioteca responsável:
WPRO
ABSTRACT
Objective:
To explore the clinical value of plasma copeptin level on major adverse cardiovascular event (MACE) occurrence in patients with acute ST-segment elevation myocardial infarction (STEMI) during hospitalization.Methods:
Our research included 2 groupsSTEMI group, n=80 and Control group, n=80 patients with stable coronary artery disease (CAD). All patients were treated in our hospital from 2012-06 to 2014-06. Plasma level of copeptin was detected by ELISA, other relevant examinations were conducted to study the MACE occurrence in STEMI patients.Results:
Plasma copeptin level in STEMI group (523.26 ± 142.69) pg/ml was higher than that in Control group (345.25 ± 89.36) pg/ml, PConclusion:
Plasma copeptin level could effectively predict MACE occurrence in patients with acute STEMI during hospitalization, it may predict their prognosis at certain point.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Chinese Circulation Journal
Ano de publicação:
2015
Tipo de documento:
Artigo